Select publications

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A Phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Do LV et al. Postoperative radiotherapy for carcinoma of the prostate: Impact on both local control and distant disease-free survival. Am J Clin Oncol 2002;25(1):1-8. Abstract

Fabozzi SJ et al. PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen Casodex. Urol Oncol 1995;1:64-66. Abstract

Freeman LM et al. The role of (111)In Capromab Pendetide (ProstaScint®) immunoscintigraphy in the management of prostate cancer. Q J Nucl Med 2002 Jun;46(2):131-7. Abstract

Grossfeld GD et al. Management of a positive surgical margin after radical prostatectomy: Decision analysis. J Urol 2000;164(1):93-9. Abstract

Hanks G et al. RTOG protocol 92-02: A Phase III trial of the use of long-term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc ASCO 2000; Abstract #1284.

Kalapurakal JA et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002;54(4):1047-54. Abstract

Kasimis B et al. Sequential therapy with the antiandrogen Casodex and castration in patients with stage D2 prostate cancer. Proc ASCO 1993;12:252. Abstract

Lange PH. PROSTASCINT® scan for staging prostate cancer. Urology 2001;57(3):402-6. Abstract

Matzkin H, Soloway MS. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma. Urology 1992;40:78-80. Abstract

Mian BM et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002;167(4):1675-80. Abstract

Moul JW et al. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am 2001;28(3):459-72. Abstract

Raj GV et al. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94(4):987- 96. Abstract

Rosenthal SA et al. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 2001;7(1):27-37. Abstract

Scolieri MJ, Resnick MI. The technique of radical perineal prostatectomy. Urol Clin North Am 2001;28(3):521-33. Abstract

See WA et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002;168(2):429-35. Abstract

Home

Editor’s Note

Gerald W Chodak, MD
    - Select publications

Thomas E Keane, MBBCh
    - Select publications

Frank A Vicini, MD
    - Select publications

William Kevin Kelly, DO
    - Select publications

Editor's Office